Related Experiment Video
Updated: Jul 10, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Bromocriptine versus levodopa in early Parkinson's disease
J J van Hilten1, C C Ramaker, Rl Stowe
1Leiden University Medical Center, Department of Neurology, P.O. Box 9600, Leiden, Netherlands, 2300 RC. J.J.van_Hilten@lumc.nl
The Cochrane Database of Systematic Reviews
|October 19, 2007
Summary
Bromocriptine (BR) may help delay motor complications like dyskinesias in early Parkinson's disease (PD) patients. However, more dropouts occurred in the BR group due to side effects or lack of efficacy.
Area of Science:
- Neurology
- Pharmacology
- Clinical Trials
Background:
- Dopamine-mimicking drugs like bromocriptine (BR) were explored for Parkinson's disease (PD) to prevent motor complications.
- The efficacy of BR monotherapy in delaying these complications remains controversial.
Purpose of the Study:
- To evaluate the effectiveness and safety of bromocriptine (BR) as a monotherapy for delaying motor complications in Parkinson's disease (PD) patients.
- To compare BR monotherapy against levodopa (LD) therapy alone in managing early PD.
Main Methods:
- Systematic review of randomized controlled trials comparing BR monotherapy to LD therapy in PD patients.
- Searches included major databases (MEDLINE, EMBASE, CENTRAL) and trial registers; data extracted by two independent reviewers.
Main Results:
- Six trials (850 participants) of low methodological quality were included; meta-analysis was not possible.
- Longer trials suggested lower dyskinesia and dystonia occurrence with BR, significant only in the largest trial.
- A trend for reduced wearing-off/on-off fluctuations with BR; however, more dropouts occurred due to side effects or inadequate response.
Conclusions:
- Bromocriptine (BR) may offer benefits in delaying motor complications and dyskinesias in early Parkinson's disease (PD).
- Comparable effects on impairment and disability were observed in patients tolerating the drug.
- Further high-quality research is needed to clarify the role of BR in PD management.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...